CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin

Molecular Cancer

Volumn 3, Issue , 2004, Pages

  Dhillon, Varinderpal S ^a   Shahid, Mohd ^b   Husain, Syed Akhtar ^b  

^a CSIRO   (Australia)

^b Department of Biosciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BRCA2 PROTEIN; BUTYRIC ACID; CYCLIN D2; FANCONI ANEMIA GROUP F PROTEIN; FRAGILE HISTIDINE TRIAD PROTEIN; HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTOR RUNX3; TRICHOSTATIN A; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ACID ANHYDRIDE HYDROLASE; CCND2 PROTEIN, HUMAN; CYCLINE; DNA BINDING PROTEIN; FANCF PROTEIN, HUMAN; RNA BINDING PROTEIN; RUNX3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ADVANCED CANCER; ARTICLE; ASTROCYTOMA; CANCER STAGING; CANCER THERAPY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CPG ISLAND; EPIGENETICS; FREQUENCY ANALYSIS; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GRANULOSA CELL TUMOR; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARY TUMOR; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; APOPTOSIS; DNA METHYLATION; DNA REPAIR; FEMALE; GENETICS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ACID ANHYDRIDE HYDROLASES; ADULT; APOPTOSIS; BRCA2 PROTEIN; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; CPG ISLANDS; CYCLIN D2; CYCLINS; DNA METHYLATION; DNA REPAIR; DNA-BINDING PROTEINS; FANCONI ANEMIA COMPLEMENTATION GROUP F PROTEIN; FEMALE; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GRANULOSA CELL TUMOR; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS;

EID: 13644254920     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-3-33     Document Type: Article

References (32)

1. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
2. Clark SJ, Melki J: DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 2002, 21: 380-5387.
3. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996, 85:17-26.
4. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M, Ishizaki K: Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Research 1998, 58: 429-3434.
5. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD: 5′-CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Research 2001, 61:3581-3585.
6. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Research 2001, 61:8659-8663.
7. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002, 8:514-519.
8. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001, 7:584-589.
9. Chang KW, Kao SY, Tzeng RJ, Liu CJ, Cheng AJ, Yang SC, Wong YK, Lin SC: Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J Pathol 2002, 196:300-306.
10. de Winter JP, Rooimans MA, van Der Weel L, van Berkel CG, Alon N, Bosnoyan-Collins L, de Groot J, Zhi Y, Waisfisz Q, Pronk JC, Arwert F, Mathew CG, Scheper RJ, Hoatlin ME, Buchwald M, Joenje H: The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Gene 2000, 24:15-26.
11. Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ, Weinberg RA: Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996, 384:470-474.
12. Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA: Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 1997, 14:1329-1340.
13. Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, Maguire S, Riley D, Coppola G, Landes GM, Madden SL, Sukumar S: Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Research 1999, 59:5464-5470.
14. Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S: Loss of Cyclin D2 Expression in the Majority of Breast Cancers Is Associated with Promoter Hypermethylation. Cancer Research 2001, 61:2782-2787.
15. Collins N, Wooster R, Stratton MR: Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 1997, 76:1150-1156.
16. Cohen MM Jr: RUNX genes, neoplasia, and cleidocranial dysplasia. Am J Med Genet 2001, 104:185-188.
17. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002, 109:113-124.
18. Arcellana-Panlilio MY, Egeler RM, Ujack E, Magliocco A, Stuart GC, Robbins SM, Coppes MJ: Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors. Genes Chromosomes Cancer 2002, 35:176-181.
19. Dhillon VS, Young AR, Husain SA, Aslam M: Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin. Br J Cancer 2004, 90:874-881.
20. Dhillon VS, Aslam A, Husain SA: The contribution of genetic and epigenetic changes in granulosa cell tumors (GCTs) of ovarian origin. Clin Cancer Res 2004, 10:5537-5545.
21. Ropke M, Boltze C, Neumann HW, Roessner A, Schneider-Stock R: Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. Pathol Res Pract 2003, 199: 37-444.
22. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002, 94:1396-1406.
23. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD: Disruption of the Fanconi-anemia-BRCA pathway in cisplastin-sensitive ovarian tumours. Nature Med 2003, 9:568-574.
24. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, Gissmann L, Durst M, Pothuri B, Murty VV: Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Research 2004, 64:2994-2997.
25. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004, 23:1000-1004.
26. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999, 21:163-167.
27. Fahrner JA, Eguchi S, Herman JG, Baylin SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Research 2002, 62:7213-7218.
28. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW, Vogelstein B: Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003, 3:89-95.
29. Lehmann U, Celikkaya G, Hasemeier B, Langer F, Kreipe H: Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 2002, 62:6634-6638.
30. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H: Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002, 160:605-612.
31. Kruk PA, Maines-Bandiera SL, Auersperg N: A simplified method to culture human ovarian surface epithelium. Lab Invest 1990, 63:132-136.
32. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826.